Skip to Content

More vaccines have protected monkeys against covid-19, suggesting they might work in people

macaque monkey
Robbie Ross | Pixabay

Studies on macaques suggest that infection with the coronavirus grants some immunity to catching it again—and that vaccines also seem to offer some protection.

The questions: Does getting infected by the coronavirus make you immune? And can a vaccine do the same job? In two studies published today in Science, a group led by researchers at Harvard University’s Beth Israel Deaconess Medical Center is answering those questions using monkeys called macaques.

Becoming immune: First, the team infected nine monkeys with the coronavirus; they developed pneumonia, just as people do. Then, after five weeks, the researchers tried infecting them again, but this time the virus didn’t take hold. That means monkeys (and possibly people) are probably immune to the virus after they catch it, although how long immunity lasts remains an open question 

Creating immunity: The group then tried out four different DNA vaccines on monkeys. These are a quick-to-design type that involve an injection into the muscle of genetic instructions to make a part of the virus called the spike protein. They found that the vaccines gave the 35 monkeys some protection from the virus—the ones that got a shot had much lower levels of virus in their respiratory tracts.

Growing evidence: Previously, two other vaccines, one from SinoVac in China and another developed by Oxford University, were also shown to protect monkeys. All told, it’s a strong signal a human vaccine could work.

Next questions: In the race to find a vaccine for billions of people, scientists need to learn more about what a correct immune response looks like, including the type and amount of antibodies that need to get generated. The team at Harvard says the results in monkeys are a step toward defining what these “correlates” of immunity are. 

Deep Dive


These scientists used CRISPR to put an alligator gene into catfish

The resulting fish appear to be more resistant to disease and could improve commercial production—should they ever be approved.

Next up for CRISPR: Gene editing for the masses?

Last year, Verve Therapeutics started the first human trial of a CRISPR treatment that could benefit most people—a signal that gene editing may be ready to go mainstream.

CRISPR for high cholesterol: 10 Breakthrough Technologies 2023

New forms of the gene-editing tool could enable treatments for common diseases.

An ALS patient set a record for communicating via a brain implant: 62 words per minute

Brain interfaces could let paralyzed people speak at almost normal speeds.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at with a list of newsletters you’d like to receive.